MS
Battle against prostate cancer gains celebrity endorsement
March 9, 2012Medical Communications M&S, MS, Vader, prostate
A famous DJ and a legendary Star Wars actor have joined forces to raise awareness of prostate cancer. Star Wars …
Rebif approved for early use in MS
January 26, 2012Sales and Marketing MS, Merck KGaA, Merck Serono, Rebif
The European Commission has approved an indication for multiple sclerosis treatment Rebif that treats early signs of the condition.This EC …
Biogen’s MS drug hits phase III targets
October 27, 2011Sales and Marketing BG-12, Biogen, MS
Biogen’s potential blockbuster MS drug BG-12 has met its primary endpoint in a late-stage trial. BG-12 (dimethyl fumarate) tablets …
MS audit finds little improvement in care
October 12, 2011MS, multiple sclerosis
There has been “little or no improvement” in the care of multiple sclerosis patients over the past five years, according …
New MS drug shows promise for Abbott
August 10, 2011Research and Development, Sales and Marketing Abbott, Avonex, Biogen, MS, gilenya
Biogen and Abbott’s multiple sclerosis drug daclizumab has performed well in a mid-stage trial, but two deaths marred the overall …
Gilenya rejected by NICE
August 5, 2011Medical Communications, Sales and Marketing MS, NICE, Novartis, gilenya
NICE has not recommended Novartis’ multiple sclerosis drug Gilenya because of its cost and ‘uncertainties over its clinical effectiveness’. Gilenya …
Actelion’s MS candidate shows promise
August 2, 2011Research and Development Actelion, MS
Actelion’s prospective multiple sclerosis pill ponesimod has cheered the company by meeting its primary endpoint in a phase IIb trial. …
Teva’s MS treatment disappoints
August 2, 2011Research and Development, Sales and Marketing Laquinimod, MS, Teva
Teva and Active Biotech’s oral MS drug laquinimod has failed to meet its primary endpoint in a phase III trial. …
Bayer wields the axe at Emeryville plant
May 31, 2011Manufacturing and Production Bayer, Emeryville, MS
Bayer Healthcare says it will cut 540 jobs at a production facility in Emeryville, California, next year after shifting production …
First oral MS pill approved in Europe
March 21, 2011Sales and Marketing MS, Novaris, fingolimod, first oral multiple sclerosis drug, gilenya, multiple sclerosis
Novartis’ Gilenya has become the first oral multiple sclerosis drug to be approved in Europe. Gilenya (fingolimod) is now licensed …
FDA knocks back Merck KGaA’s oral MS drug
March 2, 2011Sales and Marketing Cladribine, EMD Serono, FDA, MS, Merck KGaA, Movectro, multiple sclerosis, oral MS drugs
US authorities have turned down Merck KGaA’s new drug application for its oral relapsing-remitting multiple sclerosis treatment Movectro. The FDA …
Digital Pharma: Merck Serono sets up MS social network
February 18, 2011Medical Communications Digital Pharma blog, MS, Merck Serono, Movectro, Rebif, multiple sclerosis, social networking
Merck Serono has set up an international social network for multiple sclerosis patients, saying today’s pharma companies should go beyond …
Merck Serono halts Movectro European licence application
February 18, 2011Medical Communications, Sales and Marketing Cladribine, MS, Merck KGaA, Merck Serono, Movectro, fingolimod, gilenya, multiple sclerosis
Merck Serono has withdrawn its European licence application for multiple sclerosis drug Movectro. Movectro (cladribine) is a new oral treatment …
Novartis MS drug steals march over Merck rival
January 24, 2011Sales and Marketing Cladribine, MS, Merck KGaA, Novartis, fingolimod, gilenya, multiple sclerosis
Novartis’ oral multiple sclerosis Gilenya could be on the European market in just three months after winning the backing of …
Roche highlights R&D promise after setbacks
December 9, 2010Research and Development MS, Roche, oncology, personalised medicine, schizophrenia
Roche has presented its pipeline to shareholders to boost confidence that it can sustain the spectacular growth of recent years. …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
